Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib in Relapsed or Refractory Cutaneous T-Cell Lymphoma
NCT00182637Phase 2Completed
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Jul 2004
- Primary completion
- Sep 2010
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib in cutaneous T-cell lymphoma (CTCL), sponsored by UCLA Jonsson Comprehensive Cancer Center. Primary endpoint: Overall Response Rate at 2 months. Started Jul 2004; status: completed.
02
Drugs
bortezomib
03
Conditions
cutaneous T-cell lymphoma (CTCL)
Beyond the preview
Go deeper on NCT00182637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00182637.